A recent publication in Nature Metabolism unveils a promising new approach in cancer research: D-cysteine, the “mirror” form of the amino acid cysteine, can inhibit tumor growth while sparing healthy cells.
This international collaboration, involving the University of Geneva and the University of Marburg, demonstrates that D-cysteine targets NFS1, a key enzyme in iron–sulfur (Fe–S) cluster biogenesis. By disrupting Fe–S protein function, D-cysteine exposes a previously unknown metabolic vulnerability that could be exploited for cancer therapy.
Two leading scientists from MPC Therapeutics, hosted at the Fondation pour Recherches Médicales, are among the study’s authors:
Their work continues to drive MPC Therapeutics’ mission to harness mitochondrial biology for innovative cell and cancer therapies.
🔗 Read the full article on Nature Metabolism: https://rdcu.be/eBlEF
